Huperzine A is a naturally derived acetylcholinesterase inhibitor, meaning it increases the level of the neurotransmitter acetylcholine in the brain. This mechanism is primarily associated with improving memory, learning, and cognitive function. Its relevance to healthspan is focused on neuroprotection and potentially mitigating age-related cognitive decline, a critical component of maintaining quality of life.
Verdict
A targeted nootropic for cognitive support, not a core longevity agent.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
Low
EVIDENCE GRADE
B
MONTHLY COST
$5 - $20
Protocol
- Take 50-200 mcg once or twice daily, often cycled (e.g., 2-4 weeks on, 1 week off) to prevent tolerance.
Flags
- Interacts with anticholinergic drugs, beta-blockers, and other acetylcholinesterase inhibitors.
- Can cause cholinergic side effects like nausea, sweating, and blurred vision.
- Not recommended for individuals with bradycardia, epilepsy, or peptic ulcers.
- Long-term safety data in healthy individuals is limited.